Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2026-02-06 00:00:00 ET · period of report 2026-02-04 · accession 0001601830-26-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-06 | 2026-02-04 | RXRX | Gibson Christopher | Dir | S - Sale | $4.12 | -40.0K | 913.8K | -4% | -$164.8K |
| D | 2026-02-06 | 2026-02-06 | RXRX | Gibson Christopher | Dir | A - Grant | $0.00 | +30.3K | 944.2K | +3% | $0 |
| D | 2026-02-06 | 2026-02-06 | RXRX | Gibson Christopher | Dir | F - Tax | $3.56 | -10.4K | 933.8K | -1% | -$36.9K |
| D | 2026-02-06 | 2026-02-04 | RXRX | Gibson Christopher | Dir | C - Cnv Deriv | $0.00 | +40.0K | 953.8K | +4% | $0 |
| D | 2026-02-06 | 2026-02-04 | RXRX | Gibson Christopher | Dir | C - Cnv Deriv | $0.00 | -40.0K | 4.58M | -0.9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-02-04 | S | D | 40,000 | $4.12 | 913,839 | D | — | — | |
| 2 | Common | Class A Common Stock | 2026-02-06 | A | A | 30,346 | $0.00 | 944,185 | D | — | — | |
| 3 | Common | Class A Common Stock | 2026-02-06 | F | D | 10,364 | $3.56 | 933,821 | D | — | — | |
| 4 | Common | Class A Common Stock | 2026-02-04 | C | A | 40,000 | $0.00 | 953,839 | D | — | — | |
| 5 | Derivative | Class B Common Stock | 2026-02-04 | C | D | 40,000 | $0.00 | 4,583,334 | D | $0.00 · — to — | 40,000 Class A Common Stock | (F1) Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. |